Friday, March 27, 2026
HomeLocal News"UK Meningitis B Outbreak Raises Vaccination Concerns"

“UK Meningitis B Outbreak Raises Vaccination Concerns”

An invasive form of meningitis that resulted in two fatalities in Kent and led to the hospitalization of nearly a dozen individuals has sparked concerns regarding the UK’s vaccination program.

Officials from the UK Health Security Agency revealed today that the strain of bacteria responsible for the widespread outbreak in Canterbury was meningitis B, also known as menB. This strain has been spreading within the student population at the University of Kent, prompting authorities to trace tens of thousands of individuals following the deaths of a 21-year-old student and an 18-year-old named Juliette, whose father expressed profound grief over her passing.

Although meningitis B is included in the UK’s vaccination schedule, its availability has been limited until recently, prompting calls for increased distribution in light of the outbreak.

Meningitis B, or MenB, is the predominant strain of bacterial meningitis, constituting approximately 80% of invasive cases. Vaccines are available for most strains, with the MenB vaccine, introduced in 2015, demonstrating a 75% reduction in infections among vaccinated individuals.

However, the vaccine is primarily administered to infants, leaving individuals over the age of 11 without the jab unless privately obtained by their parents.

There have been appeals for extending the vaccination program to teenagers, particularly students who are identified as a high-risk group, as it could prevent severe infections. Some parents of teenagers who succumbed to meningitis B have advocated for broader administration of the vaccine, questioning whether it should be mandatory.

Dr. David Elliman, Honorary Associate Professor in Child Health at UCL GOSH Institute of Child Health, highlighted the different mechanisms of the MenB vaccine compared to other strains, emphasizing the need for continuous evaluation to determine its effectiveness and cost-efficiency.

Overall, the discussion continues on the optimal strategy for meningitis B vaccination, weighing the benefits against the resources required for wider implementation.

RELATED ARTICLES

Most Popular